English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Bristol-Myers Squibb
Press release submission
| Aug 9, 2020
BRISTOL-MYERS SQUIBB: Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma
Press release submission
| Feb 16, 2020
BRISTOL-MYERS SQUIBB: Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Carol Ostrow
| Dec 27, 2017
Restrictions on Opdivo combination trials for multiple myeloma treatment lifted by FDA
Carol Ostrow
| Dec 27, 2017
Seattle Genetics, Bristol-Myers Squibb report Hodgkin treatment study interim results
Carol Ostrow
| Dec 26, 2017
Bristol-Myers Squibb, Pfizer, others aim to raise awareness of stroke risk in atrial fibrillation patients
Robert Hadley
| Nov 8, 2017
Europe agency approves expanded use of Bristol-Myers Squibb’s Opdivo to treat advanced melanoma
Carol Ostrow
| Oct 14, 2017
Opdivo approved for treating certain liver cancer patients
Carol Ostrow
| Oct 1, 2017
AbbVie, Bristol-Myers Squibb collaborate on anti-cancer regimen to target lung tumors
Trending
+
Community
Patient Daily
| Mar 27, 2025
Healthcare professionals recognized at National Breathe Free conference for outstanding dedication
+
Regulatory
Patient Daily News Service
| Mar 28, 2025
Former HHS Official: '340B program is just one of many reminders of the abuse and waste' in D.C.
+
Pharmaceuticals
Patient Daily
| Mar 31, 2025
Founder of RXSaveCard on drug pricing: 'We typically see savings of $6,000+ per prescription'
+
Pharmaceuticals
Patient Daily
| Apr 1, 2025
American Lung Association responds to HHS budget cuts
1
2
3
»
Last »